Scott T Tagawa
Weill Medical College of Cornell University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Scott T Tagawa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00859781 · 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate CancerWeill Medical College of Cornell University · active not recruiting · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Optimization of strategies to improve NCI-sponsored clinical trial participation throughout the Weill Cornell Medicine - Meyer Cancer Center SphereR50CA285498 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · fiscal years 2024 to 2026 · $194,778 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:34 UTC. The ranking covers the 200 most relevant of 56 PubMed records, and a shared surname and initials can bring in a namesake. All 56 on PubMed
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20212,357 citationsRCR 149.5
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med · 20191,078 citationsRCR 40.4
- 480 citationsRCR 26.5
- Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Clin Cancer Res · 2013334 citationsRCR 10.5
- 305 citationsRCR 10.7
- A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.Clin Cancer Res · 2019244 citationsRCR 8.0
- Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.Sci Transl Med · 2019201 citationsRCR 6.9
- Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.J Clin Invest · 2020167 citationsRCR 6.3
- Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Lancet Oncol · 2022156 citationsRCR 9.9
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.Clin Cancer Res · 2015149 citationsRCR 5.4